Tag: TSX-V:NRX

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies¹, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsTSX-V:NRX

Myanmar Construction Industry Report 2025 | Output to Register an AAGR of 3.9% During 2026-2029, Supported by Investments in Renewable Energy, Infrastructure Projects, and...

Middlefield Canadian Income PCC – Dividend Declaration

Vistra appoints Kim Jenkins as Group Chief Executive Officer

Tag: TSX-V:NRX

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us